We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+26.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$849M
AUM Growth
+$158M
(+23%)
Cap. Flow
+$88.5M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
48.96%
Holding
87
New
21
Increased
16
Reduced
27
Closed
18
Top Buys
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$25.5M |
| 2 |
Monte Rosa Therapeutics
GLUE
|
+$18.6M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$16.9M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$16.5M |
| 5 |
Immunome
IMNM
|
+$16.1M |
Top Sells
| 1 |
ABVX
Abivax
ABVX
|
+$14.2M |
| 2 |
CG Oncology
CGON
|
+$11M |
| 3 |
Viridian Therapeutics
VRDN
|
+$10.8M |
| 4 |
Pfizer
PFE
|
+$10.4M |
| 5 |
Avalo Therapeutics
AVTX
|
+$9.52M |
Sector Composition
| 1 | Healthcare | 98.55% |
| 2 | Financials | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBIO
51
Crescent Biopharma
CBIO
$422M
| $2.4M | 0.28% |
+130,500
| New | +$1.5M |
|
52
Monopar Therapeutics
MNPR
$668M
| $2.38M | 0.28% |
+43,488
| New | +$2.63M |
|
53
Ovid Therapeutics
OVID
$459M
| $2.22M | 0.26% |
+1,000,000
| New | +$1.79M |
|
54
NextCure
NXTC
$26.8M
| $1.88M | 0.22% |
176,057
| – | – |
|
|
CMPS
55
Compass Pathways
CMPS
$1.81B
| $1.66M | 0.2% |
+300,000
| New | +$2.02M |
|
56
Neumora Therapeutics
NMRA
$293M
| $1.6M | 0.19% |
+818,156
| New | +$2.12M |
|
|
SION
57
Sionna Therapeutics
SION
$1.92B
| $1.58M | 0.19% |
39,417
-2,043
| -5% | -$78K |
|
58
TELA Bio
TELA
$33.6M
| $1.4M | 0.17% |
2,259,312
-388,200
| -15% | -$337K |
|
59
Edgewise Therapeutics
EWTX
$4.27B
| $1.34M | 0.16% |
42,615
+563
| +1% | +$16.2K |
|
60
Replimune Group
REPL
$829M
| $1.32M | 0.16% |
+171,936
| New | +$1.31M |
|
|
GENB
61
Generate Biomedicines
GENB
$1.82B
| $1.25M | 0.15% |
+100,000
| New | +$1.22M |
|
|
RADX
62
Radiopharm Theranostics
RADX
$33.9M
| $806K | 0.1% |
187,406
| – | – |
|
63
Fractyl Health
GUTS
$127M
| $779K | 0.09% |
1,701,625
-8,138,416
| -83% | -$7.5M |
|
64
iBio
IBIO
$71.5M
| $429K | 0.05% |
226,000
+120,000
| +113% | +$278K |
|
|
ADGM
65
Adagio Medical Holdings
ADGM
$12.9M
| $290K | 0.03% |
251,972
-263,412
| -51% | -$267K |
|
|
AARD
66
Aardvark Therapeutics
AARD
$137M
| $127K | 0.02% |
33,684
-270,255
| -89% | -$2.8M |
|
67
Rocket Pharmaceuticals Warrant
RCKTW
$310K
| $2.16K | ﹤0.01% |
104,828
| – | – |
|
68
Amylyx Pharmaceuticals
AMLX
$2.02B
| – | – |
-506,242
| Closed | -$6.12M |
|
|
69
Avalo Therapeutics
AVTX
$968M
| – | – |
-524,436
| Closed | -$9.52M |
|
70
CytomX Therapeutics
CTMX
$797M
| – | – |
-385,974
| Closed | -$1.64M |
|
71
4D Molecular Therapeutics
FDMT
$612M
| – | – |
-100,000
| Closed | -$750K |
|
72
Gossamer Bio
GOSS
$68.5M
| – | – |
-2,135,722
| Closed | -$6.62M |
|
73
Kymera Therapeutics
KYMR
$9.22B
| – | – |
-34,589
| Closed | -$2.69M |
|
74
Lexeo Therapeutics
LXEO
$363M
| – | – |
-617,608
| Closed | -$6.13M |
|
75
Mineralys Therapeutics
MLYS
$2.4B
| – | – |
-94,983
| Closed | -$3.45M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA